Rubicon Research: Investor Presentation, key metrics 2026

Stock snapshot: price, ranges and valuation

Rubicon Research (NSE: RUBICON, BSE: 544578) was last quoted around the ₹1,610-₹1,621 zone across snapshots shared in the data. One BSE screen showed ₹1,617.95, down ₹4.05 or 0.25%, while another quote cited ₹1,620.70 with a previous close of ₹1,653.60. The day’s trading range was reported as ₹1,610.90 to ₹1,674.90, and the 52-week range as ₹485.00 to ₹1,684.10.

Valuation metrics in the same dataset vary by source, with P/E shown at about 142.33 (and also ~142.43) on one screen and 105.5 on another, while P/B was listed near 20.26 (and also ~20.27). Dividend yield was shown at 0.09, and face value at ₹1.

Market capitalisation: around ₹26,800 crore

Rubicon Research’s market capitalisation was presented in multiple close figures: ₹26,782.24 crore on one snapshot and ₹26,801.27 crore on another. A separate line stated market cap as 273.72B, which translates to roughly ₹27,372 crore (since ₹1 billion equals ₹100 crore). These differences likely reflect timestamp and price variations across screens rather than a structural change.

What the company does: specialty pharma and complex generics

Rubicon Research Limited is described as a pharmaceutical products innovation and development enterprise headquartered in Mumbai, Maharashtra, with operating address details in Thane (Wagle Estate). It operates as a specialty pharmaceutical firm focusing on complex oral solid, liquid, ophthalmic, and injectable formulations. The business spans research, development, manufacturing, and commercialisation, including complex generic formulations, drug-device combinations, and novel drug delivery systems (NDDS) in regulated markets such as the US, Europe, and Canada.

The company’s proprietary drug-delivery technologies cited in the dataset include RubiReten, described as a gastro-retentive system for drugs with poor solubility and a limited absorption window, and RubiSRL, described as a sustained-release liquid technology using ion exchange and membrane diffusion mechanisms.

Investor presentation filing: what was disclosed

Rubicon Research informed stock exchanges about an “Investor Presentation” under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication referenced an investor presentation dated May 29, 2026, and said the material would also be uploaded on the company’s website under the Investors section.

This type of filing is typically watched by investors because it can consolidate operational commentary, segment updates, and recent performance metrics in a single document, even when it does not change formal financial disclosures.

Q2 FY26 USD revenue update and forex-related note

The dataset includes an operational update stating USD revenue of $17 million for Q2 FY26, up 33% year-on-year from $15 million in Q2 FY25. It also reported an 11.9% quarter-on-quarter increase from $12 million in Q1 FY26.

The same section noted that a part of Q2 FY26 was affected by “$ denominated costs” and mark-to-market (MTM) losses on forex hedges. No further quantification of those forex impacts was provided in the text shared.

Shareholding pattern: promoters edge down, investors inch up

Shareholding percentages across four quarters were provided for promoters and non-promoter investors. Promoter holding was shown as 59.99% in Oct 2025 and Dec 2025, easing to 59.86% in Mar 2026 and 59.76% in Jun 2026. The investor category moved in the opposite direction, from 40.01% in Oct 2025 and Dec 2025 to 40.14% in Mar 2026 and 40.24% in Jun 2026.

A separate holder list also showed General Atlantic Singapore RR Pte. Ltd. at 35.80% and Amansa Capital Pte. Ltd. at 3.12%, consistent with the investor list that included Amansa Investments Ltd around 3.12%.

IPO context included in the dataset

The text also referenced Rubicon’s IPO timeline in October 2025, stating the issue opened on October 9, 2025 and closed on October 13, 2025. The price band was listed as ₹461 to ₹485 per share, with a total issue size of ₹1,377.5 crore and a lot size of 30 shares (minimum investment ₹14,550). It also listed tentative allotment on October 14, 2025 and a tentative listing date of October 16, 2025.

On use of proceeds, the dataset stated that ₹310 crore from the fresh issue was intended largely for debt repayment. It also stated the offer-for-sale portion of ₹877.5 crore was by General Atlantic Singapore RR Pte. Ltd., noting the company would not receive proceeds from that OFS.

Key facts table

Major holders and quarterly trend

Why the update matters for investors

Two elements stand out from the information provided: first, the company’s Q2 FY26 USD revenue growth numbers, and second, the stock’s valuation multiples at current prices. A $17 million quarter, with both YoY and QoQ growth, supports the narrative of expanding scale in regulated markets, which is central to specialty and complex-generic models.

At the same time, the valuation metrics shown (P/E above 100 on two different screens, and P/B around 20) indicate the market is pricing the company at a premium to many mature pharma peers. The note on MTM losses on forex hedges also highlights a practical earnings sensitivity for export-led businesses, especially when costs are dollar-denominated.

Company contact and leadership details provided

The registered/office address included “MedOne House, Plot No. B-75, Road No. 33, Wagle Estate, Thane 400604, Maharashtra, India”, along with phone number 022-61414000 and the investor email investors@rubicon.co.in. Management names listed included Pratibha Pilgaonkar (Managing Director) and Parag Suganchand Sancheti (Executive Director and CEO). An executive table also referenced Venkat Changavalli as Independent Chairman (2025, age 73).

Conclusion

Rubicon Research’s May 2026 investor presentation filing arrived alongside strong Q2 FY26 USD revenue growth figures cited in the dataset and a stock price trading near its reported 52-week high band. Investors will likely track the next scheduled earnings report date provided as 02-09-2026 for updated financial detail and any further commentary on forex-related impacts mentioned in the Q2 FY26 note.